{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T08:46:37Z","timestamp":1770885997421,"version":"3.50.1"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,12,30]],"date-time":"2019-12-30T00:00:00Z","timestamp":1577664000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003810","name":"Hospital de Cl\u00ednicas de Porto Alegre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003810","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism Reports"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.ymgmr.2019.100564","type":"journal-article","created":{"date-parts":[[2020,1,7]],"date-time":"2020-01-07T07:36:14Z","timestamp":1578382574000},"page":"100564","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Liver involvement in patients with Gaucher disease types I and III"],"prefix":"10.1016","volume":"22","author":[{"given":"Rodrigo Tzovenos","family":"Starosta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Filippo Pinto e","family":"Vairo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Al\u00edcia Dorneles","family":"Dornelles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Su\u00e9len Porto","family":"Basgalupp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"Siebert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria L\u00facia Alves","family":"Pedroso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos Thadeu Schmidt","family":"Cerski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00e1rio Reis","family":"\u00c1lvares-da-Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ida Vanessa Doederlein","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ymgmr.2019.100564_bb0005","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18020441","article-title":"A review of Gaucher Disease pathophysiology, clinical presentation and treatments","volume":"18","author":"Stirnemann","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymgmr.2019.100564_bb0010","series-title":"Seattle, WA: GeneReviews","author":"GM","year":"2000"},{"issue":"1","key":"10.1016\/j.ymgmr.2019.100564_bb0015","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/acel.12409","article-title":"Lysosomal storage and impaired autophagy lead to inflammasome activation in Gaucher macrophages","volume":"15","author":"Aflaki","year":"2016","journal-title":"Aging Cell"},{"issue":"2","key":"10.1016\/j.ymgmr.2019.100564_bb0020","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.bcmd.2015.05.009","article-title":"Proinflammatory and proosteoclastogenic potential of peripheral blood mononuclear cells from Gaucher patients: implication for bone pathology","volume":"55","author":"Mucci","year":"2015","journal-title":"Blood Cells Mol. Dis."},{"issue":"7643","key":"10.1016\/j.ymgmr.2019.100564_bb0025","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nature21368","article-title":"Complement drives glucosylceramide accumulation and tissue inflammation in Gaucher disease","volume":"543","author":"Pandey","year":"2017","journal-title":"Nature."},{"key":"10.1016\/j.ymgmr.2019.100564_bb0030","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.smim.2018.02.006","article-title":"An unexpected player in Gaucher disease: the multiple roles of complement in disease development","volume":"37","author":"Pandey","year":"2018","journal-title":"Semin. Immunol."},{"issue":"3","key":"10.1016\/j.ymgmr.2019.100564_bb0035","doi-asserted-by":"crossref","first-page":"380","DOI":"10.4103\/1673-5374.202934","article-title":"The emerging role of autophagic-lysosomal dysfunction in Gaucher disease and Parkinson\u2019s disease","volume":"12","author":"Kinghorn","year":"2017","journal-title":"Neural Regen. Res."},{"key":"10.1016\/j.ymgmr.2019.100564_bb0040","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.neulet.2018.04.049","article-title":"The intersection of lysosomal and endoplasmic reticulum calcium with autophagy defects in lysosomal diseases","volume":"697","author":"Liu","year":"2018","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.ymgmr.2019.100564_bb0045","first-page":"31","article-title":"Quality of life of brazilian patients with Gaucher disease and fabry disease","volume":"7","author":"Oliveira","year":"2013","journal-title":"JIMD Rep."},{"issue":"1","key":"10.1016\/j.ymgmr.2019.100564_bb0050","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/mgg3.339","article-title":"Improvement of life quality measured by Lansky Score after enzymatic replacement therapy in children with Gaucher disease type 1","volume":"6","author":"Cer\u00f3n-Rodr\u00edguez","year":"2018","journal-title":"Mol Genet Genomic Med."},{"issue":"9","key":"10.1016\/j.ymgmr.2019.100564_bb0055","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1177\/1060028013500469","article-title":"Gaucher disease and its treatment options","volume":"47","author":"Bennett","year":"2013","journal-title":"Ann. Pharmacother."},{"issue":"7","key":"10.1016\/j.ymgmr.2019.100564_bb0060","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1310\/hpj5107-553","article-title":"Enzyme replacement or substrate reduction? A review of Gaucher Disease treatment options","volume":"51","author":"Van Rossum","year":"2016","journal-title":"Hosp. Pharm."},{"issue":"3","key":"10.1016\/j.ymgmr.2019.100564_bb0065","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/ajh.23382","article-title":"Velaglucerase alfa enzyme replacement therapy compared with imiglucerase in patients with Gaucher disease","volume":"88","author":"Ben Turkia","year":"2013","journal-title":"Am. J. Hematol."},{"issue":"7","key":"10.1016\/j.ymgmr.2019.100564_bb0070","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1002\/ajh.24007","article-title":"Safety and efficacy results of switch from imiglucerase to velaglucerase alfa treatment in patients with type 1 Gaucher disease","volume":"90","author":"Elstein","year":"2015","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.ymgmr.2019.100564_bb0075","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.bcmd.2015.10.002","article-title":"A multicenter, open-label extension study of velaglucerase alfa in Japanese patients with Gaucher disease: results after a cumulative treatment period of 24months","volume":"59","author":"Ida","year":"2016","journal-title":"Blood Cells Mol. Dis."},{"issue":"1","key":"10.1016\/j.ymgmr.2019.100564_bb0080","doi-asserted-by":"crossref","DOI":"10.1186\/s13023-018-0776-8","article-title":"Taliglucerase alfa: safety and efficacy across 6 clinical studies in adults and children with Gaucher disease","volume":"13","author":"Zimran","year":"2018","journal-title":"Orphanet J Rare Dis."},{"issue":"11","key":"10.1016\/j.ymgmr.2019.100564_bb0085","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1002\/ajh.24877","article-title":"Outcomes after 18 months of eliglustat therapy in treatment-na\u00efve adults with Gaucher disease type 1: the phase 3 ENGAGE trial","volume":"92","author":"Mistry","year":"2017","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.ymgmr.2019.100564_bb0090","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.bcmd.2016.10.001","article-title":"Liver involvement in Gaucher disease - Review and clinical approach","volume":"68","author":"Adar","year":"2016","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.ymgmr.2019.100564_bb0095","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.bcmd.2016.10.012","article-title":"Energy balance, glucose and lipid metabolism, cardiovascular risk and liver disease burden in adult patients with type 1 Gaucher disease","volume":"68","author":"Nascimbeni","year":"2016","journal-title":"Blood Cells Mol. Dis."},{"issue":"1-2","key":"10.1016\/j.ymgmr.2019.100564_bb0100","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ymgme.2018.08.004","article-title":"Prevalence and predictors of liver fibrosis evaluated by vibration controlled transient elastography in type 1 Gaucher disease","volume":"125","author":"Nascimbeni","year":"2018","journal-title":"Mol. Genet. Metab."},{"issue":"3","key":"10.1016\/j.ymgmr.2019.100564_bb0105","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.ymgme.2017.10.013","article-title":"Correlating liver stiffness with disease severity scoring system (DS3) values in Gaucher disease type 1 (GD1) patients","volume":"123","author":"Serai","year":"2018","journal-title":"Mol. Genet. Metab."},{"issue":"3","key":"10.1016\/j.ymgmr.2019.100564_bb0110","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.mayocpiqo.2019.04.005","article-title":"A practical guideline for hepatocellular carcinoma screening in patients at risk","volume":"3","author":"Frenette","year":"2019","journal-title":"Mayo Clin Proc Innov Qual Outcomes."},{"key":"10.1016\/j.ymgmr.2019.100564_bb0115","series-title":"Fireman MAdA. PCDT - Protocolo de Diretrizes Cl\u00ednicas e Terap\u00eauticas para Doen\u00e7a de Gaucher","first-page":"1","author":"Figueiredo","year":"2017"},{"issue":"2","key":"10.1016\/j.ymgmr.2019.100564_bb0120","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/pbc.24091","article-title":"Hyperimmunoglobulinemia in pediatric Gaucher patients in Southern Brazil","volume":"59","author":"Vairo","year":"2012","journal-title":"Pediatr. Blood Cancer"},{"issue":"1","key":"10.1016\/j.ymgmr.2019.100564_bb0125","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1590\/1678-4685-GMB-2015-0125","article-title":"The prognostic value of the serum ferritin in a southern Brazilian cohort of patients with Gaucher disease","volume":"39","author":"Koppe","year":"2016","journal-title":"Genet. Mol. Biol."},{"key":"10.1016\/j.ymgmr.2019.100564_bb0130","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.bcmd.2018.10.004","article-title":"Hepatocellular carcinoma in Gaucher disease: reinforcing the proposed guidelines","volume":"74","author":"Starosta","year":"2019","journal-title":"Blood Cells Mol. Dis."},{"issue":"2","key":"10.1016\/j.ymgmr.2019.100564_bb0135","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s13244-011-0132-1","article-title":"Quantification of iron concentration in the liver by MRI","volume":"3","author":"Al\u00fastiza Echeverr\u00eda","year":"2012","journal-title":"Insights Imaging."},{"issue":"1","key":"10.1016\/j.ymgmr.2019.100564_bb0140","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/0016-5085(81)90202-X","article-title":"LIver abnormalities in patients with Gaucher\u2019s disease","volume":"80","author":"James","year":"1981","journal-title":"Gastroenterology."},{"issue":"35","key":"10.1016\/j.ymgmr.2019.100564_bb0145","doi-asserted-by":"crossref","first-page":"4755","DOI":"10.3748\/wjg.v13.i35.4755","article-title":"Pathology of hepatic iron overload","volume":"13","author":"Deugnier","year":"2007","journal-title":"World J. Gastroenterol."},{"issue":"3","key":"10.1016\/j.ymgmr.2019.100564_bb0150","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s10545-010-9070-1","article-title":"High incidence of cholesterol gallstone disease in type 1 Gaucher disease: characterizing the biliary phenotype of type 1 Gaucher disease","volume":"33","author":"Taddei","year":"2010","journal-title":"J. Inherit. Metab. Dis."},{"issue":"11","key":"10.1016\/j.ymgmr.2019.100564_bb0155","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1002\/ajh.24491","article-title":"Glucosylsphingosine is a key biomarker of Gaucher disease","volume":"91","author":"Murugesan","year":"2016","journal-title":"Am. J. Hematol."},{"issue":"10","key":"10.1016\/j.ymgmr.2019.100564_bb0160","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18102192","article-title":"Glucosylsphingosine causes Hematological and visceral changes in mice-evidence for a pathophysiological role in Gaucher Disease","volume":"18","author":"Lukas","year":"2017","journal-title":"Int. J. Mol. Sci."},{"issue":"12","key":"10.1016\/j.ymgmr.2019.100564_bb0165","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1016\/j.bbamem.2006.08.012","article-title":"Glycosphingolipids and drug resistance","volume":"1758","author":"Gouaze-Andersson","year":"2006","journal-title":"Biochim. Biophys. Acta"},{"issue":"4","key":"10.1016\/j.ymgmr.2019.100564_bb0170","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.bbamem.2016.09.023","article-title":"Diverse relations between ABC transporters and lipids: an overview","volume":"1859","author":"Neumann","year":"2017","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ymgmr.2019.100564_bb0175","series-title":"The ABC Transporters of Human Physiology and Disease","first-page":"94","article-title":"ABCB1 and ABCG2: deciphering the role of human efflux proteins in cellular and tissue permeability","volume":"1","author":"Pires","year":"2011"},{"issue":"3","key":"10.1016\/j.ymgmr.2019.100564_bb0180","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/0005-2760(81)90279-4","article-title":"Biliary excretion of glycolipid in induced or inherited glucosylceramide lipidosis","volume":"665","author":"Pentchev","year":"1981","journal-title":"Biochim. Biophys. Acta"},{"issue":"4","key":"10.1016\/j.ymgmr.2019.100564_bb0185","doi-asserted-by":"crossref","first-page":"587","DOI":"10.3324\/haematol.2017.177816","article-title":"Involvement of hepcidin in iron metabolism dysregulation in Gaucher disease","volume":"103","author":"Lefebvre","year":"2018","journal-title":"Haematologica."},{"issue":"3","key":"10.1016\/j.ymgmr.2019.100564_bb0190","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0057507","article-title":"Liver fibrosis in type I Gaucher disease: magnetic resonance imaging, transient elastography and parameters of iron storage","volume":"8","author":"Bohte","year":"2013","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.ymgmr.2019.100564_bb0195","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1007\/s10545-018-0142-y","article-title":"Hepatocellular carcinoma in Gaucher disease: an international case series","volume":"41","author":"Regenboog","year":"2018","journal-title":"J. Inherit. Metab. Dis."},{"issue":"5","key":"10.1016\/j.ymgmr.2019.100564_bb0200","doi-asserted-by":"crossref","first-page":"727","DOI":"10.7863\/jum.2010.29.5.727","article-title":"Gaucher disease: spectrum of sonographic findings in the liver","volume":"29","author":"Hadas-Halpern","year":"2010","journal-title":"J. Ultrasound Med."},{"issue":"1","key":"10.1016\/j.ymgmr.2019.100564_bb0205","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1743-7075-10-34","article-title":"Effects of imiglucerase on the growth and metabolism of Gaucher disease type I patients: a systematic review","volume":"10","author":"Doneda","year":"2013","journal-title":"Nutr. Metab. (Lond.)"},{"issue":"4","key":"10.1016\/j.ymgmr.2019.100564_bb0210","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.clnu.2014.08.010","article-title":"Ghrelin, leptin and adiponectin levels in Gaucher disease type I patients on enzyme replacement therapy","volume":"34","author":"Doneda","year":"2015","journal-title":"Clin. Nutr."},{"issue":"6","key":"10.1016\/j.ymgmr.2019.100564_bb0215","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/MD.0b013e3182779d49","article-title":"Nonalcoholic fatty liver disease in lean individuals in the United States","volume":"91","author":"Younossi","year":"2012","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"10.1016\/j.ymgmr.2019.100564_bb0220","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3350\/cmh.2018.0037","article-title":"Recent research trends and updates on nonalcoholic fatty liver disease","volume":"25","author":"Yoo","year":"2018","journal-title":"Clin Mol Hepatol."},{"issue":"2","key":"10.1016\/j.ymgmr.2019.100564_bb0225","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1007\/s11901-016-0302-1","article-title":"Lean NAFLD: an Underrecognized outlier","volume":"15","author":"Wattacheril","year":"2016","journal-title":"Curr. Hepatol. Rep."},{"issue":"1","key":"10.1016\/j.ymgmr.2019.100564_bb0230","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3350\/cmh.2016.0109","article-title":"Genetic predisposition in nonalcoholic fatty liver disease","volume":"23","author":"Sookoian","year":"2017","journal-title":"Clin Mol Hepatol."},{"issue":"5","key":"10.1016\/j.ymgmr.2019.100564_bb0235","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/BF02396621","article-title":"Gaucher disease of the liver: CT appearance","volume":"17","author":"Glass","year":"1987","journal-title":"Pediatr. Radiol."},{"issue":"4","key":"10.1016\/j.ymgmr.2019.100564_bb0240","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1093\/qjmed\/93.4.237","article-title":"Massive hepatic fibrosis in Gaucher\u2019s disease: clinico-pathological and radiological features","volume":"93","author":"Lachmann","year":"2000","journal-title":"QJM."},{"issue":"1","key":"10.1016\/j.ymgmr.2019.100564_bb0245","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1006\/bcmd.2001.0480","article-title":"Cholelithiasis in patients with Gaucher disease","volume":"28","author":"Rosenbaum","year":"2002","journal-title":"Blood Cells Mol. Dis."},{"issue":"4","key":"10.1016\/j.ymgmr.2019.100564_bb0250","doi-asserted-by":"crossref","first-page":"447","DOI":"10.15403\/jgld.2014.1121.254.zim","article-title":"Cholelithiasis in patients with Gaucher Disease type 1: risk factors and the role of ABCG5\/ABCG8 gene variants","volume":"25","author":"Zimmermann","year":"2016","journal-title":"J Gastrointestin Liver Dis."}],"container-title":["Molecular Genetics and Metabolism Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214426919301764?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214426919301764?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T12:51:17Z","timestamp":1762001477000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2214426919301764"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":50,"alternative-id":["S2214426919301764"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgmr.2019.100564","relation":{},"ISSN":["2214-4269"],"issn-type":[{"value":"2214-4269","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Liver involvement in patients with Gaucher disease types I and III","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgmr.2019.100564","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100564"}}